
The Library
Data for Biguanide iridium(III) complexes with potent antimicrobial activity
Tools
Chen, Feng, Moat, John, McFeely, Daniel, Clarkson, Guy J., Hands-Portman, Ian, Furner-Pardoe, Jessica P., Harrison, Freya, Dowson, Christopher G. and Sadler, P. J. (2018) Data for Biguanide iridium(III) complexes with potent antimicrobial activity. [Dataset]
|
PDF
108273 WRAP-supporting-information-Chen-2018.pdf - Published Version - Requires a PDF viewer. Download (889Kb) | Preview |
|
|
PDF
HRMS for Complex1-7.pdf - Unspecified Version - Requires a PDF viewer. Download (9Mb) | Preview |
|
|
PDF
HRMS for Complex 8-14.pdf - Unspecified Version - Requires a PDF viewer. Download (10Mb) | Preview |
|
![]() |
Archive (ZIP)
1H NMR fid files for complexes 1-14.zip - Unspecified Version Download (2014Kb) |
|
![]() |
Archive (ZIP)
13C_NMR_compolexes_1_14.zip - Unspecified Version Download (2518Kb) |
Official URL: http://wrap.warwick.ac.uk/108273
Abstract
We have synthesized novel organoiridium(III) antimicrobial complexes containing a chelated biguanide, including the antidiabetic drug metformin. These 16- and 18-electron complexes were characterized by NMR, ESI-MS, elemental analysis, and X-ray crystallography. Several of these complexes exhibit potent activity against Gram-negative bacteria and Gram-positive bacteria (including methicillin-resistant Staphylococcus aureus (MRSA)) and high antifungal potency toward C. albicans and C. neoformans, with minimum inhibitory concentrations (MICs) in the nanomolar range. Importantly, the complexes exhibit low cytotoxicity toward mammalian cells, indicating high selectivity. They are highly stable in broth medium, with a low tendency to generate resistance mutations. On coadministration, they can restore the activity of vancomycin against vancomycin-resistant Enterococci (VRE). Also the complexes can disrupt and eradicate bacteria in mature biofilms. Investigations of reactions with biomolecules suggest that these organometallic complexes deliver active biguanides into microorganisms, whereas the biguanides themselves are inactive when administered alone.
Item Type: | Dataset | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Subjects: | R Medicine > RC Internal medicine | |||||||||||||||||||||
Divisions: | Faculty of Science, Engineering and Medicine > Science > Chemistry Faculty of Science, Engineering and Medicine > Science > Life Sciences (2010- ) |
|||||||||||||||||||||
Type of Data: | Zip | |||||||||||||||||||||
Library of Congress Subject Headings (LCSH): | Hypoglycemic agents, Organoiridium compounds | |||||||||||||||||||||
Publisher: | University of Warwick, Department of Chemistry | |||||||||||||||||||||
Official Date: | 23 August 2018 | |||||||||||||||||||||
Dates: |
|
|||||||||||||||||||||
Status: | Not Peer Reviewed | |||||||||||||||||||||
Publication Status: | Published | |||||||||||||||||||||
Media of Output (format): | Files | |||||||||||||||||||||
Access rights to Published version: | Open Access (Creative Commons) | |||||||||||||||||||||
Description: | Complexes 1-14 |
|||||||||||||||||||||
Date of first compliant deposit: | 17 September 2018 | |||||||||||||||||||||
Date of first compliant Open Access: | 2 August 2019 | |||||||||||||||||||||
RIOXX Funder/Project Grant: |
|
|||||||||||||||||||||
Related URLs: |
Request changes or add full text files to a record
Repository staff actions (login required)
![]() |
View Item |
Downloads
Downloads per month over past year